Updated: April 10, 2020 9:53:35 am
The Indian Council of Medical Research (ICMR) is framing a protocol for infusing blood plasma from people who have recovered from COVID-19 into patients in a serious condition. The procedure, known as convalescent plasma therapy, is carried out in the expectation that antibodies specific to the Novel Coronavirus that are present in the blood of the patient who has recovered will help generate immune response in the other patient.
This will only be done by way of a clinical trial in patients in a severe condition or on ventilator support, ICMR officials clarified. “We are in the final stages of making a protocol for convalescent plasma therapy and after that we will need approval from the Drug Controller General of India… It will be done on a trial basis. Abroad, it has been found successful in limited trials. Here we will do it only on patients on ventilator or severe patients,” Dr Manoj Murhekar, Director, ICMR-National Institute of Epidemiology, said in reply to a question about Kerala being allowed to go ahead with the trials.
The testing strategy was revised to include antibody tests in hotspots after seven days of illness. Before that, the nucleic acid-based test will have to be done.
Subscriber Only Stories
The government has announced a Rs 15,000-crore package that was promised by Prime Minister Narendra Modi in his address to the nation on March 24. While Rs 7,774 crore will be utilised for emergency response and the rest for medium-term support to be provided under mission mode approach.
The Health Ministry has asked states not to procure masks, PPEs and ventilators on their own. The items, the ministry said, would be procured and distributed centrally based on a “rational” demand of states. “Certain states have been found to be holding sufficient stocks of material with them but the field functionaries have been reported to be functioning without such equipment. The state governments should ensure timely distribution of the key equipment to field functionaries,” the letter from the ministry states.
Murhekar said the positivity rate of the 1.30 lakh samples tested so far is in the range of 3-5 per cent and the number has not changed significantly in the last 1-1.5 months. Joint Secretary in Health Ministry Lav Agarwal said supplies of PPEs, masks and ventilators have started coming. “More important than the question of whether these things are sufficient or insufficient is the point of judicious use,” he said.
Convalescent plasma therapy, which was recently allowed by USFDA for investigational purposes, banks on the age-old concept of passive immunity. This is one of several therapeutic options being tried against COVID-19 the world over.
In Kerala, Dr Anoop Kumar, member of the state-constituted expert committee for advising the government on COVID-19, said he had spoken to some who had recovered from COVID-19 and they are ready to be part of the plasma therapy trial. A key challenge, he said, is the non-availability of the kit for checking the antibody level in the plasma of a recovered person. That kit is not available in India and has to be brought from Germany and the cancellation of international flights would lead to delay, he said. — With ENS, Thiruvananthapuram
Here’s a quick Coronavirus guide from Express Explained to keep you updated: What can cause a COVID-19 patient to relapse after recovery? | COVID-19 lockdown has cleaned up the air, but this may not be good news. Here’s why | Can alternative medicine work against the coronavirus? | A five-minute test for COVID-19 has been readied, India may get it too | How India is building up defence during lockdown | Why only a fraction of those with coronavirus suffer acutely | How do healthcare workers protect themselves from getting infected? | What does it take to set up isolation wards?
📣 Join our Telegram channel (The Indian Express) for the latest news and updates
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.